for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Flexion Therapeutics Inc

FLXN.N

Latest Trade

9.08USD

Change

0.76(+9.13%)

Volume

16,507

Today's Range

8.36

 - 

9.13

52 Week Range

7.52

 - 

14.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Flexion Therapeutics Says Chief Medical Officer Scott Kelley Informed Of His Intention To Resign

April 5 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS INC - ON APRIL 2, CHIEF MEDICAL OFFICER DR. SCOTT KELLEY INFORMED OF HIS INTENTION TO RESIGN.

Flexion Therapeutics Reports Fourth-Quarter And Full-Year 2020 Financial Results

March 10 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS.FLEXION THERAPEUTICS INC - NET SALES OF ZILRETTA WERE $26.3 MILLION FOR FOURTH-QUARTER 2020.

Flexion Announces FDA Clearance Of Investigational NDA For FX301

March 1 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FX301, A NOVEL FORMULATION OF A LOCALLY ADMINISTERED NAV1.7 INHIBITOR FOR POST-OPERATIVE PAIN.FLEXION THERAPEUTICS INC - PROOF OF CONCEPT PHASE 1B CLINICAL TRIAL IN PATIENTS UNDERGOING BUNIONECTOMY EXPECTED TO BEGIN IN FIRST HALF OF 2021.

Flexion Therapeutics To Advance Investigational Gene Therapy Fx201 Into High Dose Cohort Of Phase 1 Clinical Trial In Knee Osteoarthritis And Expand Low And Mid Dose Treatment Groups

Feb 18 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS TO ADVANCE INVESTIGATIONAL GENE THERAPY FX201 INTO HIGH DOSE COHORT OF PHASE 1 CLINICAL TRIAL IN KNEE OSTEOARTHRITIS AND EXPAND LOW AND MID DOSE TREATMENT GROUPS.FLEXION THERAPEUTICS INC - COMPANY TO EXPAND FX201 LOW DOSE AND MID DOSE COHORTS TO INCLUDE UP TO 20 ADDITIONAL PATIENTS IN EACH TREATMENT GROUP.FLEXION THERAPEUTICS INC - FLEXION PLANS TO PRESENT INTERIM DATA FROM SINGLE ASCENDING DOSE PHASEAT A SCIENTIFIC MEETING IN FIRST HALF OF 2021.

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter And Full-Year 2020 Results

Jan 13 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS ANNOUNCES PRELIMINARY, UNAUDITED FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS.SEES Q4 2020 SALES $26.3 MILLION.SEES FY 2020 SALES $85.5 MILLION.Q4 REVENUE VIEW $25.7 MILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $84.9 MILLION -- REFINITIV IBES DATA.

Flexion Therapeutics Reports Third-Quarter 2020 Financial Results And Recent Business Highlights

Nov 4 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS THIRD-QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 SALES $23.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $23.5 MILLION.REMAIN ON TRACK TO FILE AN IND AND POTENTIALLY INITIATE CLINICAL TRIALS FOR FX301 IN 2021.EXPECTS 2020 TOTAL OPERATING EXPENSES WILL BE IN RANGE OF $172 MILLION TO $182 MILLION.QTRLY LOSS PER SHARE $0.50.Q4 EARNINGS PER SHARE VIEW $-0.49 -- REFINITIV IBES DATA.

Flexion Therapeutics Reports Q3 Sales Of $23.6 Mln

Oct 13 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::Q3 SALES $23.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $20.5 MILLION.

Flexion Therapeutics Files For Mixed Shelf Of Upto $300 Mln

Sept 11 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $300 MILLION - SEC FILING.

Flexion Therapeutics Reports Second-Quarter 2020 Financial Results And Recent Business Highlights

Aug 5 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::FLEXION THERAPEUTICS REPORTS SECOND-QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 SALES $15.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16.3 MILLION.REPORTED ZILRETTA NET SALES OF $15.5 MILLION IN Q2 2020.RESUMED ENROLLMENT IN PHASE 1 DOSE-ESCALATION TRIAL FOR FX201; FX301 ON TRACK TO ENTER CLINIC IN 2021.QTRLY LOSS PER SHARE $0.76.Q2 EARNINGS PER SHARE VIEW $-0.65, REVENUE VIEW $16.3 MILLION -- REFINITIV IBES DATA.

Flexion Therapeutics Reports Q2 Sales Of $15.4 Mln

July 14 (Reuters) - Flexion Therapeutics Inc <FLXN.O>::Q2 SALES $15.4 MILLION.Q2 REVENUE ESTIMATE $10.2 MILLION -- REFINITIV IBES DATA.DEMAND FOR ZILRETTA FROM HEALTHCARE PROVIDERS INCREASED MONTH-OVER-MONTH THROUGHOUT Q2 WITH TOTAL DEMAND IN LINE WITH Q1.FLEXION THERAPEUTICS - PLANS TO RECOMMENCE ZILRETTA MANUFACTURING IN Q4.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up